Xeris Biopharma (NASDAQ:XERS) Releases Earnings Results, Beats Estimates By $0.05 EPS

Xeris Biopharma (NASDAQ:XERS) posted its earnings results on Thursday. The company reported ($0.03) earnings per share for the quarter, beating the consensus estimate of ($0.08) by $0.05, Zacks reports. Xeris Biopharma updated its FY 2025 guidance to EPS.

Xeris Biopharma Stock Performance

XERS traded up $0.58 during trading on Thursday, hitting $4.35. 3,722,688 shares of the stock were exchanged, compared to its average volume of 1,686,455. The firm has a market cap of $648.95 million, a price-to-earnings ratio of -9.67 and a beta of 2.32. Xeris Biopharma has a 1 year low of $1.69 and a 1 year high of $4.50. The firm has a 50 day simple moving average of $3.54 and a 200 day simple moving average of $3.24.

Wall Street Analysts Forecast Growth

A number of research analysts have recently weighed in on the company. HC Wainwright raised their price objective on Xeris Biopharma from $6.00 to $6.60 and gave the company a “buy” rating in a research report on Monday, November 11th. Jefferies Financial Group restated a “buy” rating and set a $6.00 price target (up previously from $4.00) on shares of Xeris Biopharma in a report on Wednesday, January 29th. Finally, Piper Sandler cut Xeris Biopharma from an “overweight” rating to a “neutral” rating and set a $3.00 price objective on the stock. in a report on Monday, November 11th.

About Xeris Biopharma

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.